Fisons Ltd.

Astra Pharmaceuticals Limited

Francis Ince

John Dixon

Roger Victor Bonnert

Roger C Brown

David R Cheshire

Alan C Tinker

Brian Springthorpe

Peter A Cage

Garry Pairaudeau

Rodney A Brown

John B Farmer

Biologically active benzothiazolone ethanamines

Benzothiazolone derivatives

There are disclosed compounds of formula I,

7-(2-aminoethyl) benzothiazolones

Phenylethylamine derivatives of the formula ##STR1## wherein D.sub.1 represents a phenylethyl radical which is substituted with hydroxy and/or alkyl groups,

Phenylethylamine derivatives and pharmaceutical use

Compounds of the formula, ##STR1## in which one of R.sub.30 and R.sub.40 represents a substituted phenylalkyl group and the other of R.sub.30 and R.sub.40 represents hydrogen or halogen, and R.sub.50 and R.sub.60 each independently represent hydrogen or alkyl. The compounds of the invention are useful for the treatment or prophylaxis of renal failure or cardiovascular disease.

Substituted 3,4-dihydroxy phenylethylamino compounds

Novel compounds of the formula ##STR1## in which one of R.sub.30 and R.sub.40 represents a substituted phenylalkyl group,

##STR1## Compounds of formula (I), in which Z represent O, S, SO.sub.2, CO, NR or a single bond, G represents a one or two ring, saturated or unsaturated carbocyclic or heterocyclic group optionally substituted by phenyl thrihalomethyl or at least groups selected from alkoxy C1 to 6 or halogen atoms, provided that when Z represents a single bond G does not represent phenyl, R represents hydrogen or alkyl C1-6, m and n each independently represent 2, 3 or 4, and q represents an integer from 1 to 3 inclusive, and pharmaceutically acceptable derivatives thereof. There are also described processes for producing the compounds and pharmaceutical, e.g. cardiac, compositions containing them.

Aromatic amines

Novel 3,4-dihydroxyphenylethylamine derivatives possess dopaminergic activity in animals and are therefore useful in the treatment of iner alia congestive heart failure, renal failure and reversible obstructive airways disease. The compounds are generally administered in the form of a pharmaceutical composition comprising the active ingredient in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

3,4-Dihydroxyphenylethylamine derivatives and their use

There are described compounds of formula I, ##STR1## in which X represents a C2 to 8 alkylene chain optionally interrupted by a double bond or by S(O).sub.n, wherein n is 0, 1 or 2;

Aromatic compounds

There are provided compounds of formula I, ##STR1## and pharmaceutically acceptable derivatives thereof. There are also described the use of the compounds of formula I as pharmaceuticals, methods for making the compounds and pharmaceutical, e.g. cardiac, compositions containing the compounds.

Compounds

Dihydroxy-phenethylamino compounds useful as pharmaceuticals

There are provided paraethylamine phenol compounds of formula I, ##STR1## and pharmaceutically acceptable derivatives thereof. There are also described the use of the compounds of formula I as pharmaceuticals, methods for making the compounds and pharmaceutical, e.g. cardiac, compositions containing the compounds.

Para ethyl amino phenol pharmaceutical compounds

There are provided compounds of formula I, ##STR1## in which R.sub.1 represents OH,

Substituted 3,4-dihydroxy-phenylethylamino compounds

There are provided pharmaceutical compounds useful in treating hypertension, heart diseases and renal failure. These compounds are 4-hydroxy phenethylamines wherein the 3 position on the phenyl nucleus is occupied by either an amino, amide, carbamyl, urea sulfonamide, substituted alkyl or fluorine atom, and the amine group is further linked to another phenyl radical through an alkylene radical which may contain nitrogen, oxygen, sulfur or cyclic hydrocarbon radicals as intervening groups.

Growing community of inventors

Loughborough, United Kingdom

Francis Ince